Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM.
Manns MP, et al. Among authors: sulkowski ms.
Liver Int. 2014 May;34(5):707-19. doi: 10.1111/liv.12300. Epub 2013 Oct 9.
Liver Int. 2014.
PMID: 24118703
Clinical Trial.